Drugs News and Research

RSS

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009.

26 Mar 2015

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

26 Mar 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

Inergetics announces launch of branded CBD-based nutritional supplement

Inergetics,Inc., a world-class developer of NSF Certified nutritional and consumer health products, announced today the launch of Nulief, a branded nutritional supplement offering the holistic benefits associated with Cannabidiol (CBD).

26 Mar 2015

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross' biologics in the Russian market.

26 Mar 2015

Iceland paint a genomic picture for an entire nation

Researchers in Iceland have published the largest ever studies of whole-genome data and effectively deduced the genetic code of “an entire nation.”

26 Mar 2015

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.

26 Mar 2015

UVA researchers develop compound that could lead to improved leukemia treatments

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting "new paradigm" for treating leukemia.

26 Mar 2015

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience.

26 Mar 2015

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer's disease -- the atrophy of the part of the brain known as the hippocampus.

26 Mar 2015

Research opens door to new prostate cancer treatment

Researchers from the Centenary Institute’s Origins of Cancer Program have discovered new links between nutrition and prostate cancer.

26 Mar 2015

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

AdverseEvents Inc., a leading healthcare informatics company, today launched RxCost, the first methodology to identify the total costs of adverse drug reactions (ADRs) associated with FDA-approved drugs.

26 Mar 2015

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin.

26 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

POCP launches ePrescribing State Law Capsule in U.S.

Point-of-Care Partners, a leading health information technology (HIT) strategy and management consulting firm, has launched the ePrescribing State Law Capsule -- a recurring reference publication to simplify tracking of ePrescribing regulatory requirements in all 50 states and DC.

25 Mar 2015

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.

25 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Sun Pharma closes Ranbaxy merger

Sun Pharmaceutical Industries Ltd., today, begins the integration of Ranbaxy's business following the successful closure of its merger.

25 Mar 2015

Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

HAIR loss is one of the most distressing side-effects of cancer treatment and can even deter some patients from undergoing life-saving chemotherapy. But researchers at the University of Huddersfield are establishing the scientific basis for a rapidly-advancing scalp cooling technology that can ensure hair retention in a vast number of cases.

From Paxman 25 Mar 2015

Drugs News and Research

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Inergetics announces launch of branded CBD-based nutritional supplement

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Iceland paint a genomic picture for an entire nation

Transition announces positive results from ELND005 AME and renal clearance studies

UVA researchers develop compound that could lead to improved leukemia treatments

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

Research opens door to new prostate cancer treatment

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

POCP launches ePrescribing State Law Capsule in U.S.

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Personalized gene therapy to fight against cancer

Sun Pharma closes Ranbaxy merger

Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News